NCM
CMPX icon

New Capital Management’s Compass Therapeutics CMPX Stock Holding History

New Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,131
Closed -$41.8K – 55
2024
Q1 		$41.8K Hold
21,131
– – 0.01% 57
2023
Q4 		$33K Sell
21,131
-3,112
-13% -$5.38K 0.01% 51
2023
Q3 		$47.8K Buy
+24,243
New +$59.9K 0.02% 51
2023
Q1 		$79.3K Hold
24,243
– – 0.03% 56
2022
Q4 		$122K Hold
24,243
– – 0.05% 46
2022
Q3 		$55K Hold
24,243
– – 0.03% 41
2022
Q2 		$69K Buy
+24,243
New +$52.6K 0.04% 42
2022
Q1 		– Sell
-24,243
Closed -$77K – 48
2021
Q4 		$77K Buy
+24,243
New +$80.4K 0.04% 42

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

New Capital Management's CMPX Position: Q2 2024 in Review

New Capital Management sold out of Compass Therapeutics (CMPX) in Q2 2024, closing a stake of 21,131 shares — an estimated $41.8K sold.

New Capital Management first reported a position in CMPX in Q4 2021 and held it in 8 quarters. The position peaked at $122K in Q4 2022. 82 funds tracked by Wall St. Rank hold CMPX as of Q2 2024.

  • New Capital Management reported no remaining Compass Therapeutics position as of Q2 2024 after selling out during the quarter.
  • New Capital Management sold 21,131 Compass Therapeutics shares in Q2 2024, an estimated $41.8K.
  • New Capital Management first reported a position in Compass Therapeutics in Q4 2021 and held it in 8 quarters.
  • New Capital Management's Compass Therapeutics position peaked at $122K in Q4 2022.
  • 82 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2024.

Based on New Capital Management's 13F filing for Q2 2024, filed 11 Jul 2024.